ATARA BIOTHERAPEUTICS INC(NASDAQ:ATRA) stock News

ATRA Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

a month ago - By: Pierre Fabre Pharmaceuticals

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

a month ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

8 months ago - By: Benzinga - Mentions: BMRA WHLR DATS LFLY ...

US Stocks Edge Lower; Retail Sales Increase Less Than Expected

10 months ago - By: Benzinga - Mentions: SILV SKYX XTNT HNRG ...

Earnings Scheduled For November 12, 2024

a month ago - By: Yahoo Finance - Mentions: NVS LLY RCKT

Rocket lays off staff; Abivax capitalizes on immune drug data

2 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

4 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

4 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

4 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Pricing of $16 Million Offering

4 months ago - By: Zacks Investment Research - Mentions: FHTX

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: CGON

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

6 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

7 months ago - By: Wolf Haldenstein Adler Freeman & Herz LLP

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

7 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

7 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

7 months ago - By: The Schall Law Firm

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

7 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

7 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

8 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

9 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

10 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

10 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

10 months ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

a year ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: Atara Biotherapeutics, Inc.

ATARA BIOTHERAPEUTICS INC (ATRA) Stock News

ATRA Latest News, Press Relases and Analysis

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

US Stocks Edge Lower; Retail Sales Increase Less Than Expected

Earnings Scheduled For November 12, 2024

Rocket lays off staff; Abivax capitalizes on immune drug data

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference